Raymond James & Associates’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $7.2M | Buy |
156,763
+3,131
| +2% | +$144K | ﹤0.01% | 1411 |
|
|
2024
Q2 | $6.28M | Sell |
153,632
-142,086
| -48% | -$5.8M | ﹤0.01% | 1430 |
|
|
2024
Q1 | $7.55M | Buy |
295,718
+165,797
| +128% | +$4.23M | 0.01% | 1315 |
|
|
2023
Q4 | $1.18M | Buy |
129,921
+36,666
| +39% | +$332K | ﹤0.01% | 2417 |
|
|
2023
Q3 | $595K | Buy |
93,255
+9,815
| +12% | +$62.6K | ﹤0.01% | 2767 |
|
|
2023
Q2 | $925K | Buy |
83,440
+68,160
| +446% | +$756K | ﹤0.01% | 2507 |
|
|
2023
Q1 | $235K | Sell |
15,280
-6,333
| -29% | -$97.2K | ﹤0.01% | 3375 |
|
|
2022
Q4 | $480K | Buy |
+21,613
| New | +$480K | ﹤0.01% | 2910 |
|
|
2021
Q2 | – | Sell |
-49,643
| Closed | -$1.08M | – | 3975 |
|
|
2021
Q1 | $1.08M | Buy |
+49,643
| New | +$1.08M | ﹤0.01% | 2450 |
|